Results 161 to 170 of about 92,043 (285)

Mucous Membrane Pemphigoid After Anti‐PD‐1 Therapy: Risk‐Stratified Management and Treatment Outcomes

International Journal of Dermatology, EarlyView.
ABSTRACT Mucous membrane pemphigoid (MMP) following anti‐programmed cell death‐1 (PD‐1) therapy is rare but increasingly reported. Management of high‐ and low‐risk MMP in this setting and the potential oncologic trade‐offs remain poorly defined. We performed a narrative synthesis of all published cases of anti‐PD‐1‐associated MMP, following MEDLINE ...
Serena Dienes, Negar Esfandiari, Steven Daveluy   +2 more
wiley   +1 more source

Cost-effectiveness of proactive therapeutic drug monitoring of maintenance infliximab treatment in patients with immune-mediated inflammatory diseases: results from a randomised controlled trial. [PDF]

RMD Open
Holly T, Kirkesaether Brun M, Jørgensen KK, Goll GL, Sexton J, Gehin JE, Kvien TK, Jahnsen J, Provan SA, Bolstad N, Aas E, Haavardsholm EA, Kristiansen IS, Syversen SW, Hagen G.   +14 more
europepmc   +1 more source

Systemic Treatment and Outcome in Erythrodermic Psoriasis: A Retrospective Multicenter Study

International Journal of Dermatology, EarlyView.
This multicentre real‐world study illustrates the heterogeneity of systemic treatment approaches in erythrodermic psoriasis (EP) in Bavaria, Germany. Adverse events were more frequently observed with conventional therapies, whereas biologic therapies showed favorable outcomes.
Julian Kögel, Sandra Schuh, Julia Welzel, Michael Sticherling, Lukas Sollfrank, Carola Berking, Teodora Pumnea, Valerie Glatzel, Lars French, Felix Lauffer, Martin Valentin Vitus, Tilo Biedermann, Susanne Bauer, Michael Spindler, Mark Berneburg, Dennis Niebel   +15 more
wiley   +1 more source

Fatigue and mood disorders are highly prevalent in patients with inflammatory bowel disease: A single‐centre, cross‐sectional study using patient‐reported outcomes

Internal Medicine Journal, EarlyView.
Abstract Background Fatigue is a common and debilitating symptom in inflammatory bowel disease (IBD), yet it remains under‐recognised in clinical practice. This study aimed to quantify fatigue among Australian patients with IBD and examine associations with disease control, psychological distress and quality of life (QoL).
Andrew Chen, Darren Wong
wiley   +1 more source

Different treatments for Crohn's disease complicated by severe acute lower gastrointestinal bleeding: infliximab therapy is critical and cannot be ignored. [PDF]

Front Pharmacol
Yao S, Wang Z, Xie M, Wu S, Feng Y, Liu X, Wang F.   +6 more
europepmc   +1 more source

Intestinal transplantation in Australia: Progress, challenges and future directions

Internal Medicine Journal, EarlyView.
Abstract Background Intestinal transplant is a rare procedure reserved for patients with intestinal failure who cannot be sustained on total parenteral nutrition due to severe, life‐threatening complications. This study aims to describe the activity and outcomes of intestinal transplantation undertaken in Australia.
Brooke Chapman, Darren Wong, Graham Starkey, Marcos Perini, Jason Yap, Adam Testro   +5 more
wiley   +1 more source

A mathematical model to simulate the biological action of Infliximab on TNF- α in patients with Inflammatory Bowel Disease: the critical role of drug clearance. [PDF]

Bull Math Biol
Portillo AM, De Prado Á, Soares AJ.
europepmc   +1 more source

Deep and disseminated dermatophytosis in immunocompromised populations—A systematic review

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Dermatophyte infections of the dermis and subcutaneous tissue (i.e. deep dermatophytosis)—associated with secondary complications including pseudomycetoma and systemic dissemination—affect vulnerable populations with primary or acquired immunodeficiencies.
Aditya K. Gupta, Tong Wang, Susmita, Ditte Marie L. Saunte, Roderick Hay, Vincent Piguet   +5 more
wiley   +1 more source

Financial reimbursement incentives in the use of biosimilars for rheumatoid arthritis in Japan. [PDF]

J Pharm Policy Pract
Mamiya H, Fukasawa T, Kawakami K.
europepmc   +1 more source

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

Journal of the European Academy of Dermatology and Venereology, EarlyView.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault, Emilie Brenaut, Marie‐Emeline Marniquet, Carla Berthault, Lea Canoen, Clarisse Marcombes, Audrey Melin, Raphaël Ouakrat, Julie Charles, Stephane Mouret, Olivier Potie, Laetitia Penso, Laura Pina Vegas, Guillaume Larid, Marine Roux, Colombe Bougeard, Sandy Sylvain, Clara Labonne, Tania Randriamiarana, Da Hee Pitaud, Floriane Etheve, Jeremy Gottlieb, Laurie Gouillon, Marine Chastagner, Emilie Sbidian, Hélène Aubert, on behalf of the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), Hélène Aubert, Marie Masson Regnault, Emilie Brenaut, Emilie Sbidian, Laura Pina Vegas, Laetitia Penso, Jeremy Gottlieb, Marine Roux, Clara Labonne, Tania Randriamiarana, Floriane Etheve, Da Hee Pitaud, Marie‐Emeline Marniquet, Carla Berthault, Clarisse Marcombes, Audrey Melin, Colombe Bougeard, Julie Charles, Olivier Potie, Léa Canoen, Laurie Gouillon, Marine Chastagner, Sandy Sylvain, Guillaume Larid, Raphaël Ouakrat   +51 more
wiley   +1 more source